EPSRC IMPACT Exhibition

This exhibition was conceived by Dunne (PI) and comprised 16 mixed-media speculative design research projects. It marked the culmination of an EPSRC-funded initiative also partly supported by NESTA. Dunne supervised and then curated the projects by staff, graduates and students of the RCA Design Interactions programme. Each was conducted in collaboration with an external research partner organisation already supported by the EPSRC. The topics covered ranged from renewable energy devices and security technologies to the emerging fields of synthetic biology and quantum computing. Dunne and an advisory panel from EPSRC and NESTA selected themes on the basis of diversity of topic, design opportunities, intellectual and creative challenges, and public relevance. Dunne invited the designers to take a radical, interrogative approach, exploring the social, ethical and political implications of the research. Each designer visited the relevant science lab, consulted with the scientists throughout the project, and participated in a one-day workshop hosted by NESTA between scientists and designers on such forms of collaboration. Designers carried out literature, journal, and project surveys before developing their projects through iterative prototypes. The exhibition, held at the RCA in 2010, was considered by EPSRC to offer a powerful insight into how today’s research might transform our experience of the world. It was reviewed in the Guardian (2010), Wired (2010) and Design Week (2010). Dunne presented ‘IMPACT!’ in conferences including the IDA Congress, ‘Design at the Edges’, Taipei (2011) and at the Wellcome Trust, London (2011). He gave a related lecture to researchers at Microsoft Research Asia, Beijing (2011). Individual exhibits from the project featured in exhibitions: Museum of Modern Art (2011), National Museum of China (2011); Z33 (2010–11); Wellcome Trust (2010–11); Saint-Étienne International Design Biennial (2010); Ars Electronica (2010); The Times Cheltenham Science Festival (2010); and V2_, Institute for the Unstable Media (2010)

What If (Dublin)

Raby developed three ‘What If...’ exhibitions with Dunne (RCA), asking what role design can play in imagining possible futures and raising social, cultural and ethical questions, building on 20 years’ practice in Critical Design theorised inter alia in Dunne and Raby’s Design Noir (2001), Hertzian Tales (2005) and Speculative Everything (2013). Raby’s research included concept development, extended collaboration with exhibitors to develop their contributions, and devising the engagement strategy: all three required localised approaches to audiences, circumstances and commissioning hosts. Extensive investigation was needed in synthetic biology, nanotechnology, surveillance technologies and the domestication of natural phenomena, working with scientific partners at Imperial College and Cambridge University. ‘What If…’ Dublin (2009) comprised 29 projects envisioning hypothetical futures and was reviewed in Irish broadsheets (Examiner, Times, Independent), Wired and New Scientist: ‘the exhibits…address questions on scientific or medical ethics that must be asked in our bio-technological age’ (http://www.newscientist.com/blogs/culturelab/2009/12/post-2.html). Exhibits were also shown at the Art Institute of Chicago, Israel Museum, MoMA and Ars Electronica Center. About 1.8 million people pass the windows of the Wellcome Trust building in London annually, making them an important means of science communication. Wellcome commissioned a changing ‘What If…’ exhibition of 15 themes over 15 months (February 2010 – March 2011). Raby reconceived the design strategy with exhibits engaging at different distances, from passing buses to close-up study. The third exhibition, for the Beijing International Design Triennial (2011), explored the impact on future life of novel technologies through 58 projects in 130 exhibits from 36 designers (12 from China), for a diverse audience. The exhibition and related symposium at Tsinghua University were supported by the British Council. The Triennial was visited by approximately 500,000 visitors and featured widely, e.g. China Central Television, People's Daily, New York Times (all 2011) and Zhuangshi journal (2011 and 2012)

Between Reality and the Impossible

An illustrated catalogue essay about our contribution to the 2010 Saint-Étienne International Design Biennale

The school of constructed realities

Today we visited a new school of design developed specifically to meet the challenges and conditions of the 21st century. It offers only one degree, an MA in Constructed Realities. Having sat through the presentations for the open day, we were still a little unclear about its distinctions between real realities, unreal realities, real unrealities and unreal unrealities... (Article originally written for Maharam Stories, with permission to reprint

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans

Genome-wide association studies (GWAS) have identified numerous common prostate cancer (PrCa) susceptibility loci. We have fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in 25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16 regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of correlated variation was observed at 39 regions; 35 of which are now described by a novel more significantly associated lead SNP, while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in Europeans that had been previously reported only in East-Asian GWAS. Based on statistical evidence and linkage disequilibrium (LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region. Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the refined data for existing association signals, we estimate that these loci now explain ∼38.9% of the familial relative risk of PrCa, an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent signals within the same regio

Genetic mechanisms of critical illness in COVID-19.

Host-mediated lung inflammation is present1, and drives mortality2, in the critical illness caused by coronavirus disease 2019 (COVID-19). Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development3. Here we report the results of the GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units. We have identified and replicated the following new genome-wide significant associations: on chromosome 12q24.13 (rs10735079, P = 1.65 × 10-8) in a gene cluster that encodes antiviral restriction enzyme activators (OAS1, OAS2 and OAS3); on chromosome 19p13.2 (rs74956615, P = 2.3 × 10-8) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs2109069, P = 3.98 ×  10-12) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1 (rs2236757, P = 4.99 × 10-8) in the interferon receptor gene IFNAR2. We identified potential targets for repurposing of licensed medications: using Mendelian randomization, we found evidence that low expression of IFNAR2, or high expression of TYK2, are associated with life-threatening disease; and transcriptome-wide association in lung tissue revealed that high expression of the monocyte-macrophage chemotactic receptor CCR2 is associated with severe COVID-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammatory organ damage in COVID-19. Both mechanisms may be amenable to targeted treatment with existing drugs. However, large-scale randomized clinical trials will be essential before any change to clinical practice

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

What if ... (London)

We were commissioned by the Wellcome Trust to design the windows of their HQ on Euston Road for 2010-11. Our proposal was to use them as a mini-exhibition space where work by staff, graduates and students from the Design Interactions department at the Royal College of Art would be displayed throughout the year, six projects at a time with 3 new projects being introduced every few months. Each project is framed as a 'What If..." question presented on a chroma screen green background. Their purpose is not to offer predictions but to inspire debate about the human consequences of different technological futures, both positive and negative, by asking ‘what if…’ Graphic Design: Kellenberger-Whit

The United Micro Kingdoms: A Design Fiction

Dunne (with Raby) was commissioned by the Design Museum to produce a body of work exploring how critical and speculative design can contribute to discussions about policy and politics. It consisted of an exhibition, mixed-media design proposals, a website, talks, and public workshop. Collections such as the Wellcome Trust’s hold everyday objects from past or distant societies. When we see a strange shoe or ritualistic object we wonder what kind of society could have produced it, how it was organised, what values and beliefs motivated its citizens. We become conceptual window-shoppers, trying things out in our minds, imagining how we would interact with them, use them, and how they would affect our interactions with others. The exhibition presented designs for transport systems for a fictional, pre-apocalyptic England divided into four super-shires, each combining a different political ideology and technology. The project was an experiment in speculative material culture/fictional archaeology/imaginary anthropology. The methods were closer to fictional story-making than social science. Rigour was ensured through consultations with political scientists and engineers, not to prevent impossible scenarios but to make impossible scenarios more acceptable. Dunne aimed to introduce imaginative and radical thinking to discussions about policy and enhance understanding of how speculative design can be applied to complex issues through fact and fiction. The exhibition brought this thinking to a design audience and served as a platform for interactions between designers, the public, economists and political scientists. The project was previewed by BBC2 Culture Show (2013) and reviewed in 2013 in the national press (e.g. The Observer) and international design press (e.g. Domus, Icon Eye, Icon122, RIBA Journal). It was presented in 2013 lectures at ENSCI: Les Ateliers, Paris and Konstfack, Stockholm; and 2013 conferences including What Design Can Do, Amsterdam; Resonate (Keynote), Belgrade; Microsoft Research Design Day (Keynote), USA